Floatz logo

Eribulin Mesilate

Refractory or Recurrent Solid Tumors

Eisai Inc.Phase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Refractory or Recurrent Solid Tumors cohort.

Asset / SponsorPhaseRating
Irinotecan
Eisai Inc.
Phase 1/2CCC
Cediranib
National Cancer Institute (NCI)
Phase 1CC

Same molecule, other indications

Eribulin Mesilate is also rated in:

breast cancerDormant
B
Indicative ·
58 / 100
View asset →
adenocarcinomaDormant
CCC
Indicative ·
53 / 100
View asset →
triple-negative breast carcinomaDormant
CCC
Indicative ·
52 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →